Headaches and psychoactive substance use.

Headache

Department of Psychiatry, University of Connecticut Health Center, Farmington 06032.

Published: October 1991

A number of clinical reports have revealed an association between the use of alcohol and drugs and the onset or exacerbation of headaches. In order to investigate this association systematically and to examine the temporal relationship between onset of headaches and psychoactive substance use, we analyzed responses to a self-report questionnaire from 267 consecutive admissions to a three-week inpatient substance abuse treatment program. The response rate was 89.7%. The following characteristics were noted in the 236 respondents: 1) Over 89% reported having experienced some type of headache. 2) Headache-free individuals were significantly older than headache sufferers. 3) Women were much more likely to have migraine headaches than men. 4) Onset of migraines occurred prior to onset of substance use, while onset of tension headaches occurred after onset of substance use. Although associational data must be interpreted with caution, an intriguing hypothesis compatible with the finding is that migraines may play a role in the genesis of substance use, while substance use may play a role in the genesis of tension headaches.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1526-4610.1991.hed3109584.xDOI Listing

Publication Analysis

Top Keywords

headaches psychoactive
8
psychoactive substance
8
onset substance
8
tension headaches
8
play role
8
role genesis
8
substance
7
headaches
6
onset
6
substance number
4

Similar Publications

Research Progress on Detection of New Psychoactive Substance Piperazines .

Fa Yi Xue Za Zhi

June 2024

Shanghai Key Laboratory of Forensic Medicine, Key Laboratory of Forensic Science, Ministry of Justice, Shanghai Forensic Service Platform, Academy of Forensic Science, Shanghai 200063, China.

Piperazines are a class of new psychoactive substances with hallucinogenic effects that affect the central nervous system by affecting the level of monoamine neurotransmitters. Abuse of piperazines will produce stimulating and hallucinogenic effects, accompanied by headache, dizziness, anxiety, insomnia, vomiting, chest pain, tachycardia, hypertension and other adverse reactions, and may even cause cardiovascular diseases and multiple organ failure and lead to death, seriously affecting human physical and mental health and public safety. The abuse of new psychoactive substance piperazines has attracted extensive attention from the international community.

View Article and Find Full Text PDF

Psychotropic Drugs Reemerging as Headache Medicines.

CNS Drugs

September 2024

Neurology Service, VA Connecticut Healthcare System, MS 127, 950 Campbell Avenue, West Haven, CT, 06516, USA.

Scientific and public attention on the therapeutic effects of psychedelics and other psychoactive compounds in headache disorders has recently grown. The use and reported therapeutic effects of such treatments have long been reported, though formal clinical trials are only recently taking place. When considering how these substances might be further studied and eventually applied, it is important to consider the specific headache disorder, the particular drug, and the mode of use.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluates the clinical features and outcomes of acute cannabis toxicity versus acute synthetic cannabinoid receptor agonist toxicity in European emergency departments from 2013-2020.
  • Using data from the European Drug Emergencies Network Plus, researchers analyzed 2,657 cases of cannabis exposure and 503 cases of synthetic cannabinoid exposure to compare their effects.
  • The findings indicate that synthetic cannabinoid exposures are linked to more severe neuropsychiatric symptoms, while cannabis exposures are associated with cardiovascular issues.
View Article and Find Full Text PDF

Data on medication interactions with psychedelics are limited. Here we present what may be the first published report of a hypertensive emergency following the combination of psilocybin mushrooms with a monoamine oxidase inhibitor (MAOI). A 42-year-old man with treatment-resistant major depressive disorder took 1 g of mushrooms, while prescribed tranylcypromine, extended-release dextroamphetamine-amphetamine, and other medications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!